Anhui Huaren Health Pharmaceutical Co., Ltd. Class A

Anhui Huaren Health Pharmaceutical Co., Ltd. Class A

SSZSE:301408
12.76
CNY
-0.39
(-2.97%)
0.69EPS
23.87P/E
5.97BMarket Cap
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
3.97
4.69
5.65
7.04
9.54
9.6
11.19
13.76
14.77
Basic EPS, GAAP
0.07
0.16
0.26
0.21
0.47
0.29
0.34
0.48
0.63
Free Cash Flow per Basic Share
-0.39
0.15
-0.08
0.32
0.2
-0.21
1.01
1.72
- -
Dividend per Share
0.03
0.02
0.02
0.01
0.01
0.04
0.14
0.14
0.15
Book Value per Share
3.84
4.46
2.1
2.31
2.79
4.86
5.01
5.24
5.5
Tangible Book Value per Share
2.75
3.14
1.63
1.72
2.13
3.18
2.37
1.86
1.99
Basic Weighted Avg Shares
279
325
342
332
342
395
405
399
400
Sales/Revenue/Turnover
1,105
1,522
1,931
2,339
3,262
3,797
4,532
5,487
5,909
Operating Margin (%)
4.27
5.75
100
5.26
7.52
4.78
5.67
7.53
8.45
Depreciation Expense
5
7
59
161
165
209
292
337
- -
Net Income, GAAP
20
52
89
70
161
115
138
191
250
Effective Tax Rate (%)
47.24
30.91
27.76
25.99
25.37
22.33
25.9
27.35
28.13
Profit Margin (%)
1.77
3.41
4.61
2.98
4.93
3.02
3.04
3.49
4.23
Working Capital
107
178
187
231
338
863
419
227
217
LT Debt
- -
- -
312
303
267
569
582
627
602
Total Equity
465
542
715
785
947
1,977
2,060
2,163
2,260
Return on Invested Capital (%)
- -
8.35
9.17
5.36
10.29
4.7
4.61
6.3
- -
Return on Capital (%)
- -
13
12.63
12.04
11.56
5.34
4.4
5.55
- -
Return on Common Equity (%)
- -
10.46
14.22
9.3
18.56
7.93
6.97
9.33
- -

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
625
924
1,085
LT Borrowings
437
410
406
LT Finance Leases
209
203
197
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
400
400
400
Market Capitalization
6,800
5,752
5,972

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
2,982
2,884
3,494
Cash, Cash Equivalents & STI
999
1,029
1,522
Accounts Receivable, Net
562
499
564
Inventories
1,089
1,069
1,099
Total Current Liabilities
2,649
2,669
3,277
Payables & Accruals
- -
- -
- -
ST Debt
625
924
1,085
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
29.67%
4.98%
Free Cash Flow
- -
-257.4%
66.55%
Net Income, GAAP
- -
27.87%
38.96%
Sales/Revenue/Turnover
- -
23.48%
21.07%
Total Cash Common Dividend
- -
99.21%
1.36%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,104
1,063
1,102
1,262
4,532
2025
1,267
1,237
- -
1,594
5,487
2026
1,421
1,404
1,490
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.12
0.06
0.09
0.07
0.34
2025
0.15
0.11
- -
0.09
0.48
2026
0.2
0.14
0.2
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.11
- -
0.02
0.14
2025
0.01
0.11
- -
0.02
0.14
2026
0.01
0.12
0.01
- -
- -

Company Description

CEO
Jia Le He
Full Time Employees
8,938
Sector
Retail trade
Industry
Drugstore chains
Address
Hefei China
IPO Date
Mar 1, 2023
Website
hrjkjt.com
Business
Anhui Huaren Health Pharmaceutical Co., Ltd. is a China-based integrated healthcare enterprise primarily engaged in pharmaceutical retail, commercial agency distribution, terminal collective procurement, and pharmaceutical research, development, and manufacturing. Founded in 2001 and headquartered in Hefei, Anhui Province, the company operates an integrated business structure covering the upstream manufacturing, midstream distribution, and downstream retail segments of the pharmaceutical supply chain. The company operates through four principal business segments: Pharmaceutical Retail, Pharmaceutical Agency and Marketing, Terminal Collective Procurement, and Pharmaceutical Manufacturing and R&D. In its Pharmaceutical Retail segment, the company operates a network of directly managed retail pharmacy chains, primarily under its flagship brand Guosheng Pharmacy (Guosheng Big Pharmacy), dispensing and retailing prescription drugs; over-the-counter (OTC) medicines; traditional Chinese medicinal herbs and prepared slices; medical devices and home healthcare equipment; personal care items; and nutritional supplements. In its Pharmaceutical Agency and Marketing segment, the company serves as a nationwide marketing and commercial distribution agent for upstream pharmaceutical manufacturers, supplying proprietary and licensed drug formulations to regional pharmacy chains, medical clinics, and commercial distributors. In its Terminal Collective Procurement segment, operated primarily through its subsidiary Quanfang Pharmacy, the company provides small-to-medium retail pharmacy chains and independent drugstores with centralized drug purchasing platforms; third-party logistics and wholesale fulfillment; digital supply chain management; and retail operational enablement services. In its Pharmaceutical Manufacturing and R&D segment, operated through subsidiaries including Jiangsu Shenhua Pharmaceutical Co., Ltd. and Zhengyao Technology, the company researches, produces, and markets active pharmaceutical ingredients (APIs); medicinal fungal biotechnology formulations; chemical synthetic preparations; traditional Chinese patent medicines; and health food products. Geographically, the company concentrates its retail store footprint in East China, maintaining deep market penetration across Anhui Province and actively expanding into Jiangsu, Zhejiang, and Fujian provinces, while its pharmaceutical agency, wholesale distribution, and collective procurement platforms serve institutional clients throughout mainland China. In recent corporate developments, Anhui Huaren Health Pharmaceutical Co., Ltd. has executed an aggressive regional expansion and supply-chain integration strategy following its initial public offering on the Shenzhen Stock Exchange ChiNext board. To expand its geographic retail network outside Anhui Province, the company has completed several equity acquisitions of regional drugstore operators across East China, including acquiring controlling stakes in Zhoushan Riken Pharmaceutical Chain Co., Ltd., Ma'anshan Mandixin Pharmacy, Fujian Yangzu Huimin, Fujian Haihua Pharmaceutical, and Hangzhou Guosheng Pharmacy, while consolidating manufacturing capabilities through the acquisition of Jiangsu Shenhua Pharmaceutical Co., Ltd. Strategically shifting from retail-focused store expansion toward full-chain vertical integration, the company has initiated private placement financing programs to invest in the construction of automated sorting and intelligent logistics distribution centers, drug research and development platforms, and enterprise digitalization systems.